Board Member
Strata Critical Medical, Inc. (SRTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Strata Critical Medical, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRTA alertsMelissa Tomkiel is recorded as CEO at Strata Critical Medical, Inc. (SRTA) since August 29, 2025 and Board Member at Strata Critical Medical, Inc. (SRTA) since August 28, 2025. Strata Critical Medical, Inc. reported in an 8-K filed August 29, 2025 that Melissa Tomkiel was appointed Class III director, effective August 29, 2025. Strata Critical Medical, Inc. reported in an 8-K filed August 29, 2025 that Melissa Tomkiel was appointed co-Chief Executive Officer, effective August 29, 2025. Strata Critical Medical, Inc. reported in an 8-K filed August 4, 2025 that Melissa Tomkiel was appointed Co-CEO of Strata. Melissa Tomkiel has spoken on 4 earnings calls across 1 company, most recently for Strata Critical Medical, Inc. on November 3, 2026. Strata Critical Medical, Inc. is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at Strata Critical Medical, Inc. includes Melissa M. Tomkiel (CEO and General Counsel), Robert Wiesenthal (CEO and Chairman), Scott M. Wunsch (CEO) and 7 others.
“appointed Ms. Tomkiel to the Board as a Class III director to serve until the Company's 2027 annual stockholders meeting”
“effective as of the Closing, Melissa Tomkiel, who previously served as the Company's President and General Counsel, and William Heyburn, who previously served as the Company's Chief Financial Officer and Head of Corporate Development, assumed the roles of co-Chief Executive Officers of the Company.”
“It's now been one year since our Our strategic transformation and the beginning of strata. As Will just reviewed, the impact of our new strategy to our financial results is self-evident, but I'd like to take a few minutes to focus on our evolving and strengthening customer value proposition.”
“We are pleased to report strong results for the second quarter of 2026, highlighted by accelerating growth in our clinical business, increased cash flow generation, and great progress on our capital deployment plan.”
“We've made a great deal of progress this quarter building out our national footprint of aviation, ground, and clinical resources. This scale allows us to better and more efficiently service our customers and reduces costs for the transplant community.”
“This was a fantastic quarter for Strata, delivering excellent results and supporting our strong confidence in the future. In Q4 specifically, our organic growth of 35% was well ahead of our expectations and led us to a full year result that beat the high end of our guidance on all fronts.”
2025-08-29–present
2025-08-28–present
Medical Care Facilities · Healthcare
CEO, Board Member
2025-08-28–present
